AlphaCore Capital’s United Therapeutics UTHR Stock Holding History

AlphaCore Capital’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$509K	Buy	939 +535	+132%	+$301K	0.01%	682
2026 Q1	$240K	Buy	+404	New	+$201K	0.01%	774

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

AlphaCore Capital's UTHR Position: Q2 2026 in Review

AlphaCore Capital increased its United Therapeutics (UTHR) stake by 132% in Q2 2026, buying an estimated $301K and bringing the position to 939 shares worth $509K. The position accounts for 0.01% of the portfolio, ranked #682.

AlphaCore Capital first reported a position in UTHR in Q1 2026 and has held it in 2 quarters since. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

AlphaCore Capital held 939 shares of United Therapeutics worth $509K as of Q2 2026.
AlphaCore Capital bought 535 United Therapeutics shares in Q2 2026, an estimated $301K.
United Therapeutics made up 0.01% of AlphaCore Capital's portfolio in Q2 2026, its #682 holding.
AlphaCore Capital first reported a position in United Therapeutics in Q1 2026 and has held it in 2 quarters since.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on AlphaCore Capital's 13F filing for Q2 2026, filed 6 Aug 2026.